OrthoPediatrics stock holds steady as analysts see moderate upside
Published on 08/31/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
OrthoPediatrics Corp. stock (ISIN US68735M1027) continues to trade at a discount to Wall Street expectations as of August 31, 2026, with investors weighing ongoing losses against rising revenue and a moderate buy stance from covering analysts.
Analysts see room for OrthoPediatrics stock
Recent coverage of OrthoPediatrics points to a consensus rating characterized as a moderate buy, with a reported average price target of $26.44 for the current fiscal year. Per data cited in this coverage, analysts collectively expect the company to post a full-year earnings-per-share figure of -1.14, underlining that the growth story is still loss-making on a GAAP basis despite top-line expansion and a supportive view from the sell side.
The same analyst overview highlights that OrthoPediatrics most recently reported a quarterly loss per share of $0.26, beating the prevailing consensus estimate of a $0.30 loss by $0.04 in that period. In that quarter, revenue reached $70.51 million, ahead of the $68.21 million analysts had been modeling, underscoring the company’s ability to outgrow expectations on the top line while gradually narrowing its per-share loss.
Revenue growth offsets ongoing losses
The reported quarter in which OrthoPediatrics delivered $70.51 million in revenue also showed negative profitability metrics, including a return on equity of -8.10 percent and a net margin of -15.72 percent. These figures illustrate that, although the company is still operating in the red, its business model is scaling, with revenue coming in $2.30 million above the $68.21 million consensus for that quarter and the loss per share narrowing compared with what analysts had forecast.
For investors, the contrast between growth and losses is central. The negative net margin of 15.72 percent in that latest reported quarter indicates that every dollar of revenue still translates into a meaningful operating shortfall, yet the modest beat versus expectations on both revenue and earnings suggests the trajectory is improving. Against this backdrop, the full-year loss expectation of -1.14 EPS implies that OrthoPediatrics would need several more quarters of similar outperformance before its earnings profile turns positive.
Pediatric orthopedic implants support growth
OrthoPediatrics focuses on a portfolio of implants and instruments designed specifically for pediatric orthopedic conditions, covering areas such as deformity correction and trauma care. This specialization in children’s orthopedics differentiates the company from larger device manufacturers and helps explain its revenue growth, as health systems increasingly seek tailored solutions for younger patients and are willing to invest in dedicated pediatric platforms.
OrthoPediatrics stock valuation and outlook
With a consensus price target of $26.44 and a moderate buy rating from analysts, OrthoPediatrics stock is positioned as a growth name where investors must balance the prospect of continued revenue expansion against the clear reality of ongoing losses and negative margins. The latest reported quarter showed both a revenue beat and a smaller-than-expected loss per share, reinforcing the view that execution is trending in the right direction even as profitability remains a work in progress.
Company fact box
Company: OrthoPediatrics Corp.
ISIN: US68735M1027
Ticker: KIDS
Exchange: Nasdaq
Sector / Industry: Medical devices / Orthopedics
